Peri-graft Cytokine Profile: Influence of Hematologic Disease and Donor Type (Cytokinegreffe)
Profil Cytokinique péri-greffe : Influence de l'hémopathie et du Type de Donneur
Cytokine profiles in the early post-transplant phase may influence the Development of early post-transplant inflammatory or immunological complications. This study propose to analyze these cytokine profiles based on the disease (myelofibrosis or other hematologic malignancies) and on the donor type (haploidentical, genotypically identical, or phenotypically identical). Patients with myelofibrosis have an inflammatory cytokine profile prior to transplantation. Patients who undergo haploidentical allogeneic hematopoietic stem cell transplantation (HSCT) most often experience a post-transplant cytokine release syndrome, and the question is whether these two conditions-myelofibrosis and haploidentical transplantation-increase the probability of an early cytokine release, potentially putting these patients at greater risk for acute GVHD than patients who undergo transplantation under other conditions or who have other diseases. In the prospective Phase 2 "FIBRAPLO" protocol (ClinicalTrials.gov ID NCT04728490), 28 patients with myelofibrosis received an allogeneic hematopoietic stem cell transplantation from a haploidentical donor, and serum samples were collected at Day-7 before transplantation, Day 0 and Day+7 after transplantation to analyse cytokine profiles around the time of allogeneic HSCT.
The purpose of the present study is to match these FIBRAPLO patients (patients with myelofibrosis who received an allograft from a haploidentical donor) with patients without myelofibrosis who received a haploidentical transplant, in order to determine whether these profiles are specific to this population. The aim is to compare these profiles to other scenarios: patients with or without myelofibrosis who received transplants from 10/10 or geno-identical donors.
This study propose to prospectively collect blood samples at time points (D-7, D0, and D7) from control patients :
- receiving a haplo-identical allogeneic transplant for another condition (acute leukemia, myelodysplastic syndrome),
- a geno-identical or 10/10 matched unrelated allogeneic transplant, for myelofibrosis or for other condition (acute leukemia, myelodysplastic syndrome)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Marie Robin, MD PhD
- Numéro de téléphone: +33 01 42 49 47 60
- E-mail: marie.robin@aphp.fr
Sauvegarde des contacts de l'étude
- Nom: Jérôme Lambert
- Numéro de téléphone: 0142499742
- E-mail: jerome.lambert@u-paris.fr
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Patients aged 18 years and older
With one of the following conditions:
- Acute leukemia (AL)
- Myelofibrosis (MF)
- Myelodysplastic syndrome (MDS)
Indicated for allogeneic hematopoietic stem cell (HSC) transplantation from:
- a haploidentical donor with post-transplant cyclophosphamide OR
- a geno-identical donor, without post-transplant cyclophosphamide OR
- a pheno-identical donor, without post-transplant cyclophosphamide
Exclusion Criteria:
- Lymphoma
- Non-malignant disease
- Patient's refusal to participate in this study
- Patient's refusal to have their data recorded in the EBMT registry
- Transplant from an unrelated donor 9/10
- Person under legal guardianship or curatorship, or unable to give informed consent
- Person subject to judicial protective measures, or deprived of liberty by a judicial or administrative decision
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
MF-Haplo
Patients with myelofibrosis receiving a haplo-identical allogeneic transplant
|
Blood sampling at D-7, D0 and D+7 from allogeneic transplantation
|
|
MF-10/10
Patients with myelofibrosis receiving a geno- or pheno-identical allogeneic transplant
|
Blood sampling at D-7, D0 and D+7 from allogeneic transplantation
|
|
AL-haplo
Patients with acute leukemia or myelodysplastic syndrome receiving a haplo-identical allogeneic transplant
|
Blood sampling at D-7, D0 and D+7 from allogeneic transplantation
|
|
AL-10/10
Patients with acute leukemia or myelodysplastic syndrome a geno- or pheno-identical allogeneic transplant
|
Blood sampling at D-7, D0 and D+7 from allogeneic transplantation
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
GVHD panel 2 cytokines in haplo-identical transplantation
Délai: At day 7
|
Comparison of ST2 and REG3α dosages between MF-haplo and AL-haplo patients
|
At day 7
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cytokine level
Délai: Up to day 7
|
Changes in cytokine levels before and after transplantation comparison according the hematologic condition and the type of allogeneic transplantation between Day -7 and Day 0, and between Day 0 and Day +7
|
Up to day 7
|
|
Cytokine profile
Délai: 7 days before allogeneic transplantation
|
Peri-graft cytokine profile, comparison according the hematologic condition and the type of allogeneic transplantation
|
7 days before allogeneic transplantation
|
|
Cytokine profile
Délai: the day of allogeneic transplantation
|
Peri-graft cytokine profile, comparison according the hematologic condition and the type of allogeneic transplantation
|
the day of allogeneic transplantation
|
|
Cytokine profile
Délai: 7 days after allogeneic transplantation
|
Peri-graft cytokine profile, comparison according the hematologic condition and the type of allogeneic transplantation
|
7 days after allogeneic transplantation
|
|
Occurrence of early acute GVHD
Délai: 45 days after transplantation
|
Occurrence of early acute GVHD ; comparison according the hematologic condition and the type of allogeneic transplantation
|
45 days after transplantation
|
|
Overall survival
Délai: At 12 months
|
Overall survival; defined as the time from Day 0 to death from any cause ; comparison according the hematologic condition and the type of allogeneic transplantation
|
At 12 months
|
|
Non-relapse mortality
Délai: At 6 months
|
At 6 months
|
|
|
Non-relapse mortality
Délai: At 12 months
|
At 12 months
|
|
|
Incidence of toxicities
Délai: Up to 45 days after transplantation
|
CTCAE Grade >1
|
Up to 45 days after transplantation
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies hématologiques
- Maladies de la moelle osseuse
- Troubles myéloprolifératifs
- Maladies hémiques et lymphatiques
- Syndromes myélodysplasiques
- Myélofibrose primaire
- Techniques d'investigation
- Manipulation des échantillons
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Perforation
- Procédures chirurgicales, opératoires
- Collection d'échantillons de sang
Autres numéros d'identification d'étude
- APHP260773
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .